KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Operations (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Cash from Operations for 13 consecutive years, with 81481000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 49.82% to 81481000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 279118000.0 through Dec 2025, down 53.88% year-over-year, with the annual reading at 279118000.0 for FY2025, 53.88% down from the prior year.
  • Cash from Operations for Q4 2025 was 81481000.0 at Xenon Pharmaceuticals, down from 71752000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 13077000.0 in Q2 2021, with the low at 81481000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 39107450.0, with a median of 34870500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations grew 11.01% in 2022, then crashed 106.19% in 2025.
  • Over 5 years, Cash from Operations stood at 20710000.0 in 2021, then crashed by 70.59% to 35330000.0 in 2022, then dropped by 0.2% to 35401000.0 in 2023, then tumbled by 53.63% to 54385000.0 in 2024, then tumbled by 49.82% to 81481000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 81481000.0, 71752000.0, and 64233000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.